Document is current

Article History

Received: 4 March 2026

Accepted: 24 April 2026

First Online: 20 May 2026

Declarations

:

: Bruno Viaggi has the following conflicts of interest: Abbott, Accelerate Diagnostics, Ada, Advanz Pharma, Alifax, Angelini, Becton Dickinson, Bellco, Biomerieux, Biotest, Cepheid, Correvio, Dasit, Diasorin, Emmegi Diagnostica, Gilead, InfectoPharm, Menarini, MercK Sharp & Dohme, Mundipharma, Nordic Pharma, Pfizer, Roche Diagnostics, Shionogi, Thermofischer Scientific, and Viatris. Gianmaria Rossolini reports grants or contracts to the laboratory from Ada, Alifax, Angelini, Arrow Diagnostics, Biomedical Service, bioMérieux, Cepheid, Copan, Menarini , MSD, Qlinea, Qvella, SD Biosensor, Seegene, and Shionogi; consulting fees from Advanz Pharma, bioMérieux, Deepull, MSD, and Viatris; honoraria for lectures, presentations, manuscript writing, or educational events from bioMérieux, Menarini, MSD, Pfizer, Shionogi, and Relab. Tommaso Giani reports grants or contracts to the laboratory from Alifax, Angelini, Arrow Diagnostics, bioMérieux, Menarini, and MSD, and consulting fees from Advanz Pharma, and bioMérieux. Emanuele Palomba, Andrea Gori, Alberto Farese, and Marta Colaneri declare that they have no competing interests.

: The treatment was administered as an Early Access Program and approved by a local ethics committee. Written informed consent for treatment and publication was obtained from the patient’s legal representatives, in accordance with the Declaration of Helsinki.